Senti Biosciences(SNTI)
$0.09-0.01 (-10.31%)
SNTI
Senti Biosciences financials statements
$0.09
At close:-0.01 (-10.31%)
Want to see SNTI full AI Analyst Report?
Senti Biosciences (SNTI) Ratios
270 Followers
Senti Biosciences Ratios
SNTI's free cash flow for Q2 2026 was $-14.25M. For the 2026 fiscal year, SNTI's free cash flow was increased by $0.00 and operating cash flow was $-14.25M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 |
| Quick Ratio | 1.67 | 4.49 | 5.62 | 5.68 | 4.04 |
| Cash Ratio | 1.18 | 3.67 | 2.84 | 3.19 | 3.85 |
| Solvency Ratio | -1.27 | -0.65 | -1.25 | -1.01 | -1.44 |
| Operating Cash Flow Ratio | -3.11 | -3.15 | -4.13 | -1.93 | -2.38 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -19.87 |
| Net Current Asset Value | $ -22.36M | $ -13.23M | $ 18.63M | $ 49.05M | $ 22.42M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.56 | 0.34 | 0.32 | 0.21 | 0.24 |
| Debt-to-Equity Ratio | 5.17 | 1.31 | 0.56 | 0.29 | 0.38 |
| Debt-to-Capital Ratio | 0.84 | 0.57 | 0.36 | 0.23 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 9.16 | 3.81 | 1.79 | 1.42 | 1.60 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -21.48 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.13 | 7.32 | 8.49 | 8.44 | 5.21 |
| Net Debt to EBITDA | -0.22 | 0.27 | -0.03 | 0.35 | 0.89 |
| Profitability Margins | |||||
| Gross Profit Margin | -16431.82% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -279263.64% | 0.00% | -3375.38% | -1889.35% | -1765.43% |
| EBITDA Margin | -262731.82% | 0.00% | -3100.91% | -1770.05% | -1634.05% |
| Operating Profit Margin | -289668.18% | 0.00% | -4687.92% | -1889.35% | -1765.43% |
| Pretax Profit Margin | -279263.64% | 0.00% | -4216.68% | -1511.41% | -2414.62% |
| Net Profit Margin | -279263.64% | 0.00% | -3592.42% | -1771.45% | -2414.62% |
| Continuous Operations Profit Margin | -279263.64% | 0.00% | -4216.68% | -1511.41% | -2414.62% |
| Net Income Per EBT | 100.00% | 100.00% | 85.20% | 117.21% | 100.00% |
| EBT Per EBIT | 96.41% | 86.49% | 89.95% | 80.00% | 136.77% |
| Return on Assets (ROA) | -119.94% | -53.95% | -59.47% | -32.20% | -57.21% |
| Return on Equity (ROE) | -1099.27% | -205.82% | -106.19% | -45.74% | -91.62% |
| Return on Capital Employed (ROCE) | -171.08% | -72.07% | -86.81% | -38.15% | -49.23% |
| Return on Invested Capital (ROIC) | -149.67% | -68.24% | -83.58% | -37.69% | -48.21% |
| Return on Tangible Assets | -119.94% | -53.95% | -59.47% | -32.20% | -57.21% |
| Earnings Yield | -26.27% | -327.24% | -242.64% | -93.94% | -12.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 0.00 | 0.11 | 5.25 | 4.74 |
| Payables Turnover | 1.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.05 | 0.04 | 0.07 |
| Asset Turnover | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.03 | 0.05 | 0.06 |
| Cash Conversion Cycle | 26167.15 | 0.00 | 3266.92 | 69.53 | 76.95 |
| Days of Sales Outstanding | 26462.50 | 0.00 | 3266.92 | 69.53 | 76.95 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 295.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 26462.50 | 0.00 | 3266.92 | 69.53 | 76.95 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.19 | -9.01 | -11.81 | -7.94 | -7.93 |
| Free Cash Flow Per Share | -0.19 | -9.01 | -14.52 | -17.35 | -9.20 |
| Dividend Paid and CapEx Coverage Ratio | -221.65 | -1592.19 | -4.35 | -0.84 | -6.25 |
| Capital Expenditure Coverage Ratio | -221.65 | -1592.19 | -4.35 | -0.84 | -6.25 |
| Operating Cash Flow Coverage Ratio | -1.50 | -1.23 | -1.39 | -0.94 | -1.52 |
| Operating Cash Flow to Sales Ratio | -1974.73 | 0.00 | -26.49 | -10.62 | -15.12 |
| Free Cash Flow Yield | -18.66% | -256.78% | -220.02% | -123.08% | -9.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.38 | -0.31 | -0.41 | -1.06 | -7.78 |
| Price-to-Sales (P/S) Ratio | 10628.51 | 0.00 | 14.81 | 18.86 | 187.89 |
| Price-to-Book (P/B) Ratio | 41.84 | 0.63 | 0.44 | 0.49 | 7.13 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.36 | -0.39 | -0.45 | -0.81 | -10.71 |
| Price-to-Operating Cash Flow Ratio | -5.38 | -0.39 | -0.56 | -1.78 | -12.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.01 | -0.01 | -0.23 | -0.04 |
| Enterprise Value Multiple | -4.26 | -0.03 | -0.51 | -0.71 | -10.61 |
| Enterprise Value | 246.30M | 1.50M | 31.03M | 41.44M | 397.16M |
| EV to EBITDA | -4.26 | -0.03 | -0.51 | -0.71 | -10.61 |
| EV to Sales | 11195.38 | 0.00 | 15.69 | 12.61 | 173.35 |
| EV to Free Cash Flow | -5.64 | -0.04 | -0.48 | -0.54 | -9.88 |
| EV to Operating Cash Flow | -5.67 | -0.04 | -0.59 | -1.19 | -11.47 |
| Tangible Book Value Per Share | 0.02 | 5.58 | 15.08 | 28.96 | 13.83 |
| Shareholders’ Equity Per Share | 0.02 | 5.58 | 15.08 | 28.96 | 13.83 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.45 | 0.75 | 0.52 |
| Net Income Per Share | -0.27 | -11.49 | -16.01 | -13.25 | -12.67 |
| Tax Burden | 1.00 | 1.00 | 0.85 | 1.17 | 1.00 |
| Interest Burden | 1.00 | 0.87 | 1.25 | 0.80 | 1.37 |
| Research & Development to Revenue | 1708.45 | 0.00 | 16.25 | 8.57 | 9.58 |
| SG&A to Revenue | 1189.23 | 0.00 | 17.63 | 11.45 | 9.28 |
| Stock-Based Compensation to Revenue | 259.36 | 0.00 | 4.89 | 4.99 | 1.00 |
| Income Quality | 0.71 | 0.78 | 0.74 | 0.60 | 0.63 |
Currency in USD

